B+
Bull case
20%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
IMNN
ImunonANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Phase 2 survival signal, favorable monitoring-committee reviews and enrollment ahead of plan support a potentially valuable frontline ovarian-cancer program if Phase 3 confirms overall survival. [#PR-2026-09-24] Company update.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Event-driven Phase 3 interim analyses have no disclosed dates or assured positive outcome.
Momentum
93
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.95 · Bull $2.20 · Bear $0.35Analysis 2026-10-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum93 · Δ7d -
Value41 · Δ7d -0.1
Sentiment84 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Event-driven Phase 3 interim analyses have no disclosed dates or assured positive outcome.
- • June 30 cash of $6.9 million and first-half operating cash use of $7.0 million point to substantial financing risk before the targeted 2029 enrollment completion.
- • Phase 2 was not powered for survival, pivotal confirmation is years away, and funding needs could erode common-equity value before a decisive readout.
Catalyst clock
2026-12-31
Financing terms and cash-runway scrutiny
Lead driver: Sentiment · See AI snapshot
Momentum
93
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
84
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 93.5 / Value 40.7 / Sentiment 83.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$4.67M
Beta
2.13
Shares Out
5.61M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.21
Rev YoY
-100.0%
EPS YoY
-71.0%
Gross Margin
-387.2%
Op Margin
-
Net Debt
-$7.77M
Current Ratio
1.82
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data